|
Platelet transfusion refractoriness is the failure to achieve the desired level of blood platelets in a patient following a platelet transfusion. The cause of refractoriness may be either immune or nonimmune based. Among immune-related refractoriness, antibodies against HLA antigens are the primary cause. Non-immune causes include splenomegaly (enlargement of the spleen), fever, and recent chemotherapy.〔 〕 ==Diagnosis== Platelet transfusion refractoriness is typically diagnosed using the ''corrected count increment'', which requires 4 items of information: #Pre-transfusion platelet count #Post-transfusion platelet count: the post-transfusion blood sample for this measurement should be collected 10–60 minutes after the transfusion has been completed #Body surface area #Number of platelets transfused: the blood bank maintains records of the estimated number of platelets in each unit. Current requirements in the US stipulate that a unit of apheresis platelets must contain at least 3.0 x1011 platelets. The CCI is calculated as follows: CCI= (Post-transfusion platelet count - Pre-transfusion platelet count)(BSA) ÷ (number of platelets transfused). A CCI greater than 7500 indicates a sufficient post-transfusion increment, whereas a CCI less than 7500 is considered diagnostic of platelet refractoriness. Immune-mediated refractoriness usually shows little or no increment in the immediate post-transfusion platelet count. Non-immune refractoriness may show an initial rise in platelet count, but a subsequent 8-hour or 12-hour post-transfusion sample shows a return to the baseline platelet count. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「platelet transfusion refractoriness」の詳細全文を読む スポンサード リンク
|